<?xml version='1.0' encoding='utf-8'?>
<document id="18509769"><sentence text="[Anidulafungin]." /><sentence text="Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency"><entity charOffset="0-13" id="DDI-PubMed.18509769.s2.e0" text="Anidulafungin" /><entity charOffset="23-35" id="DDI-PubMed.18509769.s2.e1" text="echinocandin" /><pair ddi="false" e1="DDI-PubMed.18509769.s2.e0" e2="DDI-PubMed.18509769.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18509769.s2.e0" e2="DDI-PubMed.18509769.s2.e1" /></sentence><sentence text=" As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this avoiding toxicity problems"><entity charOffset="10-23" id="DDI-PubMed.18509769.s3.e0" text="echinocandins" /></sentence><sentence text=" It has fungicidal activity against many Candida spp" /><sentence text=", including fluconazole-resistant, and fungistatic activity against other yeast and moulds such as Aspergillus spp"><entity charOffset="12-23" id="DDI-PubMed.18509769.s5.e0" text="fluconazole" /></sentence><sentence text=" Clinical trials have shown non-inferiority of anidulafungin to fluconazole for invasive, including candidemia, and non-invasive Candida infections"><entity charOffset="47-60" id="DDI-PubMed.18509769.s6.e0" text="anidulafungin" /><entity charOffset="64-75" id="DDI-PubMed.18509769.s6.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.18509769.s6.e0" e2="DDI-PubMed.18509769.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18509769.s6.e0" e2="DDI-PubMed.18509769.s6.e1" /></sentence><sentence text=" It is well-tolerated, and no drug-related serious adverse events have been reported" /><sentence text=" Anidulafungin, which has a very long half life, is slowly degraded by human peptidases and proteases and has a low drug-drug interaction profile based on its lack of interaction with the cytochrome P450 system"><entity charOffset="1-14" id="DDI-PubMed.18509769.s8.e0" text="Anidulafungin" /></sentence><sentence text=" Thus, dosing adjustments of anidulafungin based on age, gender, body weight, disease status, concomitant therapy or renal or hepatic insufficiency is not necessary"><entity charOffset="29-42" id="DDI-PubMed.18509769.s9.e0" text="anidulafungin" /></sentence><sentence text=" As it does not interact with amphotericin B and voriconazole, cyclosporine, tacrolimus and other drugs, it can be used in combination with other antifungal agents and co-administered with immunosuppressant drugs"><entity charOffset="30-44" id="DDI-PubMed.18509769.s10.e0" text="amphotericin B" /><entity charOffset="49-61" id="DDI-PubMed.18509769.s10.e1" text="voriconazole" /><entity charOffset="63-75" id="DDI-PubMed.18509769.s10.e2" text="cyclosporine" /><entity charOffset="77-87" id="DDI-PubMed.18509769.s10.e3" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e0" e2="DDI-PubMed.18509769.s10.e0" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e0" e2="DDI-PubMed.18509769.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e0" e2="DDI-PubMed.18509769.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e0" e2="DDI-PubMed.18509769.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e1" e2="DDI-PubMed.18509769.s10.e1" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e1" e2="DDI-PubMed.18509769.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e1" e2="DDI-PubMed.18509769.s10.e3" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e2" e2="DDI-PubMed.18509769.s10.e2" /><pair ddi="false" e1="DDI-PubMed.18509769.s10.e2" e2="DDI-PubMed.18509769.s10.e3" /></sentence><sentence text=" It is generally well-tolerated in clinical trials" /><sentence text=" Its most frequent adverse events are nausea, vomiting, moderate diarrhea, transient elevation of hepatic enzymes and headache" /><sentence text=" Some of the patients have mild, passing reactions such as facial blushing, nausea and dyspnea related with rapid intravenous perfusion" /><sentence text=" Its antifungal activity, clinical efficacy, safety profile, and pharmacokinetic characteristics make it a suitable alternative antifungal compound for therapy of mucosal candidiasis, candidemia and invasive candidiasis, above all in patients with some degree of renal and hepatic insufficiency" /><sentence text="" /></document>